Analytical Data
-
Gene name
BCA-1/CXCL13
- Application
-
Alternative Names
(Angie)(B cell-attracting chemokine 1)(BCA-1)(B lymphocyte chemoattractant)(CXC chemokine BLC)(Small-inducible cytokine B13)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43927
-
Expression Region
23-109aa
-
Protein Length
Partial
-
Molecular Weight
17.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCA-1, also known as CXCL13, is a chemokine that plays a critical role in the immune system by facilitating the migration of B cells to lymphoid tissues. It is primarily produced by lymphoid stromal cells and is essential for the organization of lymphoid follicles. The study of BCA-1/CXCL13 has gained significant attention due to its implications in various autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, where aberrant B cell accumulation in tissues contributes to disease pathology. Additionally, the role of BCA-1/CXCL13 in cancer biology, particularly in tumor microenvironments, has emerged as a pivotal area of research, as it may influence tumor progression and metastasis by modulating immune cell infiltration and activation. Recombinant BCA-1/CXCL13 protein is increasingly being utilized in research to dissect its biological functions, understand receptor interactions, and explore its potential as a therapeutic target. Moreover, manipulation of BCA-1/CXCL13 pathways could provide novel strategies for enhancing vaccine responses or developing immunotherapies. By elucidating the mechanisms through which BCA-1/CXCL13 operates, researchers aim to identify new intervention points for diseases characterized by dysregulated immune responses, thereby expanding therapeutic options and improving clinical outcomes.
